Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib

Recruiting now

Conditions studied: Metastatic Renal Cell Carcinoma

In brief

CABOGEN is a Observational, retrospective, multicenter study that will enroll patients with metastatic clear cell renal carcinoma (mccRCC) treated with cabozantinib after one or more previous lines of treatment that included TKIs, immune checkpoint inhibitors or mTOR inhibitors.

Key facts

Study ID: NCT06548867
Run by: Gruppo Oncologico Italiano di Ricerca Clinica
People needed: 80
Starts: 2024-05-28
Expected to finish: 2025-06-30
Last updated by the study team: 2024-08-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age ≥ 18 years.
Patients with histological diagnosis of predominantly clear cell carcinoma
Availability of the tumor tissue from the primary tumor and/or a metastatic site for the genomic profiling analysis not older than 5 years.
Evaluable disease according to RECIST criteria v 1.1
Treatment with cabozantinib after one or more previous therapies for mRCC
Patient progressed from the start to cabozantinib therapy within 3 months or after 9 months
Any prognosis group according to the IMDC risk score
Signed informed consent must be obtained for living patients. Patients who died and patient untraceable will be analyzed based on the Authorization no. 9/2016 of the Italian Data Protector Supervisor.

You may not qualify if…

Non-availability of tumor tissue from the primary tumor or a metastatic site for biomarker analysis
Patient progressed between 3 and 9 months from the beginning of treatment with cabozantinib.
Non-availability of clinical information useful to evaluate the IMDC risk group at baseline.

Where it is running

AUSL-IRCCS of Reggio Emilia — Reggio Emilia, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.